EC approves Maviret, AbbVie reports earnings

AbbVie Inc. (NYSE:ABBV) reported 2Q17 earnings Friday and said the European Commission approved Maviret glecaprevir/pibrentasvir to treat chronic HCV genotypes 1-6 infection in adults. The fixed-dose combination is indicated for previously untreated patients without cirrhosis. It is also under Priority Review by FDA.

AbbVie and Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) discovered glecaprevir (ABT-493), a next-generation HCV NS3/4A protease inhibitor, under a 2006 deal. AbbVie developed pibrentasvir (ABT-530), a next-generation HCV NS5A protein inhibitor...